Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

LUNAR-2: TTFields med Pembrolizumab + platinabaserad kemoterapi för metastatisk NSCLC (LUNAR-2)

11 november 2026 uppdaterad av: NovoCure GmbH

LUNAR-2: Pivotal, randomiserad, öppen studie av tumörbehandlingsfält (TTFields, 150 kHz) samtidigt med Pembrolizumab och platinabaserad kemoterapi för behandling av metastaserad icke-småcellig lungcancer

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Studieöversikt

Detaljerad beskrivning

LUNAR-2 is a pivotal, randomized, open-label study that aims to evaluate the effectiveness and safety of Tumor Treating Fields (TTFields) concomitantly administered with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC).

The primary objectives of the study are to assess overall survival (OS) and progression-free survival (PFS) in subjects treated with TTFields, pembrolizumab, and platinum-based chemotherapy compared to those treated with pembrolizumab and platinum-based chemotherapy alone. PFS will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

The secondary endpoints of this study will evaluate PFS and OS, stratified by the specific histological subtype of NSCLC and PD-L1 Tumor Proportion Score (TPS).

The population will consist of subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and will be stratified as follow:

  1. Histology - Squamous vs. non-squamous
  2. PD-L1 expression level - TPS <1% vs. 1% ≤TPS <50% vs. TPS ≥50%
  3. Prior treatment with immunotherapy - yes vs. no

The study will be conducted globally at approximately 130 participating sites. The study device, NovoTTF-200T, is a portable, battery-operated system that delivers TTFields at a frequency of 150kHz. It utilizes insulated transducer arrays to deliver electric forces intended to disrupt cancer cell division.

Studietyp

Interventionell

Inskrivning (Beräknad)

734

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Brussels, Belgien, 1200
        • Aktiv, inte rekryterande
        • Cliniques universitaires Saint-Luc
      • Ghent, Belgien, 9000
        • Aktiv, inte rekryterande
        • AZ Maria Middelares - Campus Maria Middelares
      • Créteil, Frankrike, 94010
        • Rekrytering
        • Centre Hospitalier Intercommunal de Creteil
        • Kontakt:
      • Limoges, Frankrike, 87000
        • Avslutad
        • CHU Limoges
      • Marseille, Frankrike, 13003
        • Avslutad
        • Hopital Europeen
      • Nantes, Frankrike, 44277
        • Rekrytering
        • Hopital Prive du Confluent
        • Huvudutredare:
          • Cyriac Blonz
        • Kontakt:
      • Paris, Frankrike, 75005
      • Pessac, Frankrike, 33604
      • Pierre-Bénite, Frankrike, 69495
        • Avslutad
        • Centre Hospitalier Lyon Sud
      • Strasbourg, Frankrike, 67091
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35209
        • Avslutad
        • Central Alabama Research
    • Arizona
      • Goodyear, Arizona, Förenta staterna, 85338
        • Aktiv, inte rekryterande
        • Western Regional Medical Center, LLC
    • California
      • Fullerton, California, Förenta staterna, 92835
      • Newport Beach, California, Förenta staterna, 92663
        • Rekrytering
        • Hoag Family Cancer Institute - Hoag Memorial Hospital
        • Kontakt:
      • Sacramento, California, Förenta staterna, 95816
        • Aktiv, inte rekryterande
        • Sutter Institute for Medical Research
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32207
        • Rekrytering
        • Baptist MD Anderson Cancer Center, Baptist Health
        • Kontakt:
        • Huvudutredare:
          • John Vu
      • Ocala, Florida, Förenta staterna, 34474
        • Avslutad
        • Florida Cancer Affiliates - Ocala Oncology
      • Tampa, Florida, Förenta staterna, 33612
    • Illinois
      • Barrington, Illinois, Förenta staterna, 60010
        • Aktiv, inte rekryterande
        • Northwest Oncology & Hematology
      • Elmhurst, Illinois, Förenta staterna, 60126
        • Aktiv, inte rekryterande
        • Elmhurst Hospital Nancy Knowles Cancer Center
      • Naperville, Illinois, Förenta staterna, 60540-6766
        • Avslutad
        • Edward Cancer Center
      • Zion, Illinois, Förenta staterna, 60099
        • Rekrytering
        • Cancer Treatment Centers of America (CTCA)
        • Kontakt:
    • Indiana
      • Fort Wayne, Indiana, Förenta staterna, 46845
        • Rekrytering
        • Parkview Packnett Family Cancer Institute
        • Huvudutredare:
          • Brian Chang
        • Kontakt:
      • Indianapolis, Indiana, Förenta staterna, 46237
        • Avslutad
        • Franciscan Health Indianapolis
    • Kansas
      • Westwood, Kansas, Förenta staterna, 66205
        • Aktiv, inte rekryterande
        • University of Kansas Cancer Center
    • Maryland
      • Annapolis, Maryland, Förenta staterna, 21401
        • Avslutad
        • Luminis Health Radiation Oncology - Anne Arundel Health System
    • Missouri
      • Kansas City, Missouri, Förenta staterna, 64154
        • Aktiv, inte rekryterande
        • University of Kansas Cancer Center - North
      • Lee's Summit, Missouri, Förenta staterna, 64064
        • Aktiv, inte rekryterande
        • University of Kansas Cancer Center - Lee's Summit
      • Overland, Missouri, Förenta staterna, 66210
        • Aktiv, inte rekryterande
        • University of Kansas Cancer Center - Overland Park
    • New York
      • New Hyde Park, New York, Förenta staterna, 11042
        • Avslutad
        • New York Cancer & Blood Specialists (NYCBS)
      • New York, New York, Förenta staterna, 10028
        • Avslutad
        • New York Cancer & Blood Specialists (NYCBS)
      • Rochester, New York, Förenta staterna, 14642
        • Avslutad
        • University of Rochester Medical Center
      • Shirley, New York, Förenta staterna, 11967
        • Avslutad
        • New York Cancer & Blood Specialists (NYCBS)
      • The Bronx, New York, Förenta staterna, 10469
        • Avslutad
        • New York Cancer & Blood Specialists (NYCBS)
    • North Carolina
      • Cary, North Carolina, Förenta staterna, 27518
        • Rekrytering
        • WakeMed Health & Hospitals
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
      • Pittsburgh, Pennsylvania, Förenta staterna, 15212
        • Rekrytering
        • AHN Cancer Center
        • Kontakt:
    • Texas
      • Dallas, Texas, Förenta staterna, 75235
      • Dallas, Texas, Förenta staterna, 75235
      • Edinburg, Texas, Förenta staterna, 78539
        • Rekrytering
        • DHR Health Oncology Institute
        • Kontakt:
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • Houston Methodist Cancer Center
        • Huvudutredare:
          • Jun Zhang
        • Kontakt:
      • Richardson, Texas, Förenta staterna, 75082
        • Rekrytering
        • Methodist Richardson Cancer Center
        • Kontakt:
      • San Antonio, Texas, Förenta staterna, 78229
        • Avslutad
        • Jason Bates at University of Texas Health Science Center
    • Washington
      • Auburn, Washington, Förenta staterna, 98001
        • Avslutad
        • MultiCare Regional Cancer Center
      • Gig Harbor, Washington, Förenta staterna, 98335
        • Avslutad
        • MultiCare Regional Cancer Center
      • Puyallup, Washington, Förenta staterna, 98372
        • Avslutad
        • MultiCare Regional Cancer Center
      • Spokane, Washington, Förenta staterna, 99218
        • Avslutad
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Tacoma, Washington, Förenta staterna, 98405
        • Avslutad
        • MultiCare Institute for Research & Innovation
      • Afula, Israel, 1834111
        • Aktiv, inte rekryterande
        • Emek Medical Center
      • Haifa, Israel, 34561
        • Aktiv, inte rekryterande
        • Bnai zion MC
      • Alessandria, Italien, 15121
        • Avslutad
        • A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria
      • Bergamo, Italien, 24125
        • Aktiv, inte rekryterande
        • Humanitas Gavazzeni
      • Ferrara, Italien, 44124
        • Aktiv, inte rekryterande
        • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
      • Meldola, Italien, 47014
        • Rekrytering
        • IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino Amadori
        • Kontakt:
      • Pesaro, Italien, 61122
        • Aktiv, inte rekryterande
        • Azienda Sanitaria Territoriale Pesaro Urbino
      • Roma, Italien, 00128
        • Avslutad
        • Universita Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario
      • Rome, Italien, 00186
        • Avslutad
        • Ospedale Isola Tiberina Gemelli
      • Siena, Italien, 53100
        • Avslutad
        • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
    • Osaka
      • Osaka, Osaka, Japan, 541-8567
        • Rekrytering
        • Osaka International Cancer Institute
        • Kontakt:
        • Huvudutredare:
          • Kei Kunimasa
      • Sakai, Osaka, Japan, 590-0197
        • Rekrytering
        • Kindai University Hospital
        • Huvudutredare:
          • Hidetoshi Hayashi
        • Kontakt:
    • Saitama
      • Hidaka, Saitama, Japan, 350-1298
        • Rekrytering
        • Saitama Medical University International Medical Center
        • Kontakt:
    • Tokyo
      • Bunkyo, Tokyo, Japan, 113-8431
        • Rekrytering
        • Juntendo University
        • Huvudutredare:
          • Takehito Shukuya
        • Kontakt:
      • Chuo-ku, Tokyo, Japan, 104-0045
        • Rekrytering
        • National Cancer Center Hospital
        • Huvudutredare:
          • Hidehito Horinouchi
        • Kontakt:
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Rekrytering
        • Cross Cancer Institute/University of Alberta
        • Kontakt:
        • Huvudutredare:
          • Haidar El Darsa
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Rekrytering
        • The Ottawa Hospital Cancer Centre General Campus
        • Huvudutredare:
          • Garth Nicholas
        • Kontakt:
      • Toronto, Ontario, Kanada, M4N 3M5
        • Rekrytering
        • Sunnybrook Health Sciences Center
        • Kontakt:
        • Huvudutredare:
          • Susanna Cheng
    • Quebec
      • Montreal, Quebec, Kanada, H2L 4M1
      • Arnhem, Nederländerna, 6815AD
        • Avslutad
        • Rijnstate Ziekenhuis
      • Friesland, Nederländerna, 8934 AD
        • Avslutad
        • Medisch Centrum Leeuwarden (MCL) - Oncologisch Centrum Leeuwarden (OCL)
      • Harderwijk, Nederländerna, 3844 DG
        • Aktiv, inte rekryterande
        • St. Jansdal ziekenhuis
      • Utrecht, Nederländerna, 3543 AZ
        • Avslutad
        • St Antonius Ziekenhuis
      • Poznan, Polen, 60-693
        • Avslutad
        • Uniwersytecki Szpital Kliniczny
      • Baden, Schweiz, 5404
        • Avslutad
        • Cantonal Hospital Baden
      • Fribourg, Schweiz, 1752
        • Aktiv, inte rekryterande
        • HFR Freiburg-Kantonsspital
      • Singapore, Singapore, 168583
        • Aktiv, inte rekryterande
        • NCCS Singapore
      • Singapore, Singapore, 329563
        • Avslutad
        • Curie Oncology
      • Singapore, Singapore, 574623
        • Aktiv, inte rekryterande
        • Icon Cancer Centre Singapore (Singapore Oncology Consultants)
      • Barcelona, Spanien, 8916
        • Rekrytering
        • Institut Catala d'Oncologia
        • Kontakt:
      • Lleida, Spanien, 25198
        • Aktiv, inte rekryterande
        • Hospital Universitario Arnau de Vilanova
      • Madrid, Spanien, 28027
        • Aktiv, inte rekryterande
        • Clinica Universidad de Navarra (Madrid)
      • Madrid, Spanien, 28034
        • Avslutad
        • Hospital Ruber Internacional
      • Málaga, Spanien, 29010
        • Rekrytering
        • Hospital Regional Universitario de Malaga
        • Kontakt:
      • Pamplona, Spanien, 31008
        • Rekrytering
        • Clinica Universidad de Navarra
        • Kontakt:
          • Miguel Fernandez de Sanmamed Gutierrez
          • Telefonnummer: +34 948255400
          • E-post: msanmamed@unav.es
    • Alicante
      • Elche, Alicante, Spanien, 3293
        • Avslutad
        • Hospital Universitario del Vinalopo
    • Andalusia
      • Seville, Andalusia, Spanien, 41013
        • Aktiv, inte rekryterande
        • Hospital Universitario Virgen del Rocio
    • Catalonia
      • Barcelona, Catalonia, Spanien, 8017
        • Rekrytering
        • Clinica Mi Tres Torres Barcelona - Giromed Institute
        • Kontakt:
    • Madrid
      • Torrejón de Ardoz, Madrid, Spanien, 28850
        • Rekrytering
        • Hospital Universitario de Torrejon
        • Kontakt:
    • Greater London
      • London, Greater London, Storbritannien
        • Rekrytering
        • Charing Cross Hospital
        • Kontakt:
        • Huvudutredare:
          • Waleed Mohammed
    • Leicestershire
      • Leicester, Leicestershire, Storbritannien, LE1 5WW
        • Rekrytering
        • University Hospitals of Leicester NHS Trust
        • Kontakt:
        • Huvudutredare:
          • Sean Dulloo
    • London
      • London, London, Storbritannien, SW3 6JJ
        • Rekrytering
        • The Royal Marsden NHS Foundation Trust
        • Kontakt:
    • Merseyside
      • Liverpool, Merseyside, Storbritannien, L7 8YA
        • Rekrytering
        • Clatterbridge Cancer Centre - Liverpool
        • Huvudutredare:
          • Carles Escriu
        • Kontakt:
    • Sutton
      • Sutton, Sutton, Storbritannien, SM2 5PT
        • Rekrytering
        • The Royal Marsden NHS Foundation Trust - Sutton
        • Kontakt:
      • Olomouc, Tjeckien, 779 00
        • Avslutad
        • Fakultni nemocnice Olomouc FNOL
      • Ostrava, Tjeckien, 70300
        • Aktiv, inte rekryterande
        • Nemocnice Agel Ostrava-Vitkovice / Agel Ostrava-Vitkovice Hospital
      • Prague, Tjeckien, 12808
        • Aktiv, inte rekryterande
        • General University Hospital in Prague
      • Berlin, Tyskland, 13125
        • Aktiv, inte rekryterande
        • Evangelische Lungenklinik Berlin
      • Giessen, Tyskland, 35392
      • Halle, Tyskland, 06120
        • Rekrytering
        • Krankenhaus Martha-Maria Halle-Dolau
        • Huvudutredare:
          • Wolfgang Schuette
        • Kontakt:
      • Heidelberg, Tyskland, 69126
        • Aktiv, inte rekryterande
        • Thoraxklinik Heidelberg
      • Löwenstein, Tyskland, 74245
        • Avslutad
        • Klinik Loewenstein gGmbH
      • Oldenburg, Tyskland, 26121
        • Avslutad
        • Pius-Hospital Oldenburg
      • Farkasgyepű, Ungern, 8582
        • Aktiv, inte rekryterande
        • Farkasgyepui Tudogyogyintezet
      • Kecskemét, Ungern, 6000
        • Aktiv, inte rekryterande
        • Bacs-Kiskun Varmegyei Oktatokorhaz
      • Szekszárd, Ungern, 7100
        • Rekrytering
        • Tolna Varmegyei Balassa Janos Korhaz
        • Kontakt:
      • Innsbruck, Österrike, 6020
        • Aktiv, inte rekryterande
        • Universitaetsklinik fuer Innere Medizin V Innsbruck
      • Salzburg, Österrike, 5020
        • Aktiv, inte rekryterande
        • University Hospital Salzburg
      • Vienna, Österrike, 1210
        • Aktiv, inte rekryterande
        • Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  • ≥22 years of age in the USA

    ≥18 years of age outside of the USA.

  • Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer [AJCC] criteria) non-squamous or squamous NSCLC.

  • Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.

  • Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.

  • ECOG Performance Status (PS) of 0-1.

  • Adequate hematologic and end-organ function

    o For subjects not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN (unless participant is receiving anticoagulant therapy as long as INR or aPTT is within therapeutic range of intended use of anticoagulants).

  • A female participant is eligible to participate if she is not pregnant, not breastfeeding

  • If male subject with a female partner(s) of child-bearing potential, must agree to use an effective contraception

  • All subjects must sign written informed consent.

Exclusion Criteria:

All individuals meeting any of the following exclusion criteria will be excluded from study participation:

  • Mixed small cell and NSCLC histology.

  • EGFR sensitizing mutation and/or ALK translocation, and/or ROS1 and/or RET targetable gene rearrangement, and/or METex14 skipping mutation, and/or NTRK1/2 gene fusion and/or BRAF V600 mutations directed therapy is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.

  • Has received systemic therapy for metastatic disease.

  • Had major surgery <3 weeks prior to randomization

  • Received radiation therapy to the lung that is > 30 Gy within 6 months of randomization.

  • Has received prior radiotherapy within 2 weeks of randomization. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

  • Is expected to require any other form of antineoplastic therapy while on study.

  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.

    • Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
  • Has symptomatic Central Nervous System (CNS) metastases and/or carcinomatous meningitis. Subjects with asymptomatic CNS metastases or with previously treated brain metastases may participate provided they were treated before randomization (if applicable) and are neurologically stable and without requirement of steroid treatment for at least 7 days prior to randomization.

  • Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior randomization. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.

  • Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms in the 12 months prior to randomization.

  • Participation in another clinical study with an investigational agent or device during the 4 weeks prior to randomization.

  • Concurrent treatment with other experimental treatments for NSCLC while in the study.

  • Has a known sensitivity to any component of the planned systemic therapies (pembrolizumab, cisplatin/carboplatin, pemetrexed/paclitaxel/nab-paclitaxel) .

  • Pregnant or breastfeeding

  • Admitted to an institution by administrative or court order.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy

Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy.

The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.

Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.

Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

Aktiv komparator: Arm 2: Pembrolizumab and Platinum-based Chemotherapy

Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy.

Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.

Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival (OS)
Tidsram: up to 6 years

To compare OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to OS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis).

up to 6 years
Progression Free Survival (PFS)
Tidsram: up to 6 years

To compare PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to PFS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis)

up to 6 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression Free Survival (PFS)
Tidsram: up to 6 years

Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology.

up to 6 years
Overall Survival (OS)
Tidsram: up to 6 years

Overall Survival (OS) in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology.

up to 6 years
Progression Free Survival (PFS)
Tidsram: up to 6 years

PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 Tumor Proportion Score (TPS).

up to 6 years
Overall Survival (OS)
Tidsram: up to 6 years

OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 TPS.

up to 6 years
Progression Free Survival (PFS)
Tidsram: up to 6 years

PFS per RECIST v1.1 as assessed by BICR at 6 (PFS6), 12 (PFS12), 24 (PFS24), and 36 (PFS36) months in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
1, 2, and 3-year Survival Rate
Tidsram: up to 6 years

1-, 2- and 3-year survival rate in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Objective Response Rate (ORR)
Tidsram: up to 6 years

Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Duration of Response (DoR)
Tidsram: up to 6 years

Duration of Response (DoR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Disease Control Rate (DCR)
Tidsram: up to 6 years

Disease Control Rate (DCR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Progression Free Survival (PFS)
Tidsram: up to 6 years

PFS per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Objective Response Rate (ORR)
Tidsram: up to 6 years

ORR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Duration of Response (DoR)
Tidsram: up to 6 years

DoR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Disease Control Rate (DCR)
Tidsram: up to 6 years

DCR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone.

up to 6 years
Adverse Events
Tidsram: up to 6 years

Toxicity profile of TTFields concomitant with pembrolizumab and platinum-based chemotherapy. The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments.

up to 6 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

31 juli 2024

Primärt slutförande (Beräknad)

1 oktober 2028

Avslutad studie (Beräknad)

1 oktober 2028

Studieregistreringsdatum

Först inskickad

29 december 2023

Först inskickad som uppfyllde QC-kriterierna

10 januari 2024

Första postat (Faktisk)

22 januari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 december 2025

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera